Artivion (NYSE:AORT) CAO Amy Horton Sells 901 Shares

Artivion, Inc. (NYSE:AORT) CAO Amy Horton sold 901 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total transaction of $34,039.78. Following the completion of the sale, the chief accounting officer directly owned 139,088 shares of the company’s stock, valued at $5,254,744.64. The trade was a 0.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Amy Horton also recently made the following trade(s):

• On Monday, March 2nd, Amy Horton sold 641 shares of Artivion stock. The stock was sold at an average price of $38.02, for a total transaction of $24,370.82.
• On Tuesday, February 24th, Amy Horton sold 830 shares of Artivion stock. The shares were sold at an average price of $35.69, for a total value of $29,622.70.
• On Monday, February 23rd, Amy Horton sold 1,731 shares of Artivion stock. The stock was sold at an average price of $37.59, for a total value of $65,068.29.
• On Monday, December 8th, Amy Horton sold 4,572 shares of Artivion stock. The stock was sold at an average price of $44.42, for a total value of $203,088.24.

Artivion Stock Down 1.7%

AORT traded down $0.65 on Thursday, hitting $37.85. The company had a trading volume of 136,722 shares, compared to its average volume of 411,654. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of 189.26 and a beta of 1.60. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. The stock has a fifty day moving average price of $41.42 and a 200-day moving average price of $42.92. Artivion, Inc. has a 12-month low of $21.97 and a 12-month high of $48.25.

Artivion (NYSE:AORT) last released its quarterly earnings results on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The business had revenue of $118.30 million for the quarter, compared to analysts’ expectations of $116.42 million. The firm’s quarterly revenue was up 19.2% compared to the same quarter last year. Analysts predict that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on AORT. Wall Street Zen downgraded Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Stifel Nicolaus set a $55.00 target price on shares of Artivion in a research note on Thursday. Oppenheimer restated an “outperform” rating and set a $50.00 price target on shares of Artivion in a research note on Friday, November 7th. Needham & Company LLC reiterated a “buy” rating and set a $58.00 price objective on shares of Artivion in a research note on Monday, February 2nd. Finally, Citizens Jmp upped their target price on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Artivion has an average rating of “Moderate Buy” and a consensus price target of $50.47.

Trending Headlines about Artivion

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Management will present virtually at the Oppenheimer Healthcare MedTech & Services Conference — a near‑term event where management can update guidance, commercialization progress or product milestones that could re‑ignite buy‑side interest. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Recent quarterly results beat estimates (EPS and revenue) with ~19% YoY revenue growth — this underpins the growth story and supports analyst conviction. MarketBeat – Artivion Earnings Summary
• Positive Sentiment: Large institutional buying (notably Invesco’s sizable Q4 add and other funds increasing exposure) can provide steadier bid support and signals professional investor confidence. MarketBeat – Institutional Activity
• Neutral Sentiment: Analyst coverage remains constructive (consensus “Moderate Buy” with an average target ≈ $49) — supportive but much of this view may already be reflected in the stock. MarketBeat – Analyst Ratings
• Neutral Sentiment: Industry/media pieces highlight portfolio expansion and relative EPS performance on the NYSE Composite; useful for narrative but not an immediate market catalyst by itself. Kalkine – Portfolio Expansion Article
• Negative Sentiment: A concentrated wave of insider sales occurred March 2–4 (CEO James Mackin sold tens of thousands of shares across filings, plus multiple EVP/SVP/CAO sales). Markets often interpret clustered senior‑level selling as a near‑term negative catalyst even though insiders retain large stakes and sales can be for liquidity/tax planning. Monitor for additional filings or company commentary. Insider Trades Alert

Institutional Investors Weigh In On Artivion

Hedge funds have recently modified their holdings of the stock. Summit Partners Public Asset Management LLC acquired a new stake in shares of Artivion during the 4th quarter valued at approximately $39,401,000. Invesco Ltd. raised its holdings in Artivion by 211.9% during the fourth quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock worth $50,228,000 after purchasing an additional 748,119 shares during the last quarter. Champlain Investment Partners LLC purchased a new stake in Artivion during the third quarter worth $17,912,000. Goldman Sachs Group Inc. grew its holdings in Artivion by 144.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 537,375 shares of the company’s stock valued at $24,510,000 after purchasing an additional 317,518 shares during the last quarter. Finally, Two Sigma Investments LP increased its position in shares of Artivion by 235.5% in the third quarter. Two Sigma Investments LP now owns 446,535 shares of the company’s stock valued at $18,906,000 after buying an additional 313,446 shares in the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.